Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Argus Health
Cantor Fitzgerald
Citi
Boehringer Ingelheim
Federal Trade Commission
Johnson and Johnson
Merck
US Department of Justice

Generated: December 14, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

« Back to Dashboard

Clinical Trials for Metformin Hydrochloride; Saxagliptin Hydrochloride

Trial ID Title Status Sponsor Phase Summary
NCT00121641 Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise Completed AstraZeneca Phase 3 The purpose of this clinical research study is to learn whether saxagliptin (BMS-477118) is more effective than placebo as a treatment for type 2 diabetic subjects who are not sufficiently controlled with diet and exercise
NCT00121667 Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone Completed AstraZeneca Phase 3 The purpose of this clinical research study is to learn whether Saxagliptin added to Metformin therapy is more effective than Metformin alone as a treatment for type 2 diabetic subjects who are not sufficiently controlled with Metformin alone
NCT00327015 A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise Completed AstraZeneca Phase 3 The purpose of this trial is to understand if adding saxagliptin to metformin therapy is safe and works better than taking either saxagliptin or metformin alone
NCT00575588 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period Completed Bristol-Myers Squibb Phase 3 Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to assess the efficacy and tolerability of saxagliptin in addition to metformin and compare to sulphonylurea in addition with metformin.
NCT00575588 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period Completed AstraZeneca Phase 3 Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to assess the efficacy and tolerability of saxagliptin in addition to metformin and compare to sulphonylurea in addition with metformin.
NCT00661362 Evaluate Efficacy and Safety of Saxagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Completed Bristol-Myers Squibb Phase 3 Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to evaluate the efficacy and safety in adult patients who have inadequate glycaemic control when treated with metformin in addition to diet and exercise.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Metformin Hydrochloride; Saxagliptin Hydrochloride

Condition Name

Condition Name for Metformin Hydrochloride; Saxagliptin Hydrochloride
Intervention Trials
Type 2 Diabetes Mellitus 18
Type 2 Diabetes 16
Diabetes Mellitus, Type 2 8
Type2 Diabetes Mellitus 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Metformin Hydrochloride; Saxagliptin Hydrochloride
Intervention Trials
Diabetes Mellitus, Type 2 48
Diabetes Mellitus 46
Glucose Intolerance 2
Prediabetic State 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Metformin Hydrochloride; Saxagliptin Hydrochloride

Trials by Country

Trials by Country for Metformin Hydrochloride; Saxagliptin Hydrochloride
Location Trials
United States 282
Mexico 52
Canada 49
United Kingdom 37
Italy 25
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Metformin Hydrochloride; Saxagliptin Hydrochloride
Location Trials
Texas 22
California 17
Florida 15
Ohio 13
South Carolina 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Metformin Hydrochloride; Saxagliptin Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Metformin Hydrochloride; Saxagliptin Hydrochloride
Clinical Trial Phase Trials
Phase 4 15
Phase 3 26
Phase 2 1
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Metformin Hydrochloride; Saxagliptin Hydrochloride
Clinical Trial Phase Trials
Completed 34
Not yet recruiting 7
Recruiting 6
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Metformin Hydrochloride; Saxagliptin Hydrochloride

Sponsor Name

Sponsor Name for Metformin Hydrochloride; Saxagliptin Hydrochloride
Sponsor Trials
AstraZeneca 49
Bristol-Myers Squibb 10
The University of Texas Health Science Center at San Antonio 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Metformin Hydrochloride; Saxagliptin Hydrochloride
Sponsor Trials
Industry 62
Other 33
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Accenture
McKesson
Argus Health
Fish and Richardson
Boehringer Ingelheim
US Army
Teva
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.